Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Pre-operative nucleosome liquid biopsy for risk stratification of lung cancer

Monday, December 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at NACLC 2025 discusses the use of a pre-operative nucleosome liquid biopsy for risk stratification in lung cancer patients. The research emphasizes the prognostic value of the Nu.Q® Cancer Test, which could enhance patient outcomes. This innovative approach may lead to more personalized treatment strategies in oncology.
Price reaction · baseline $5.994 (2025-12-05 close) · hit pre-market · 5 other VNRX headline(s) in the window, move may be shared
day 0 close
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at NACLC 2025 highlights innovative research.
  • Potential for improved risk stratification in lung cancer.
  • Nu.Q® Cancer Test shows promising prognostic value.

Full Press Release Details

Poster titled: Pre-operative nucleosome liquid biopsy for risk stratification of lung cancer
Pei-Hsing Chen, Chia-Wei Weng, Tai-Horng Young, T.-P. Lu, D. Pamart, A. Kotronoulas, M. Herzog, J. Micallef, Hsao-Hsun Hsu, Jin-Shing Chen
Presented at NACLC 2025

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the NACLC 2025 presentation?

The presentation focuses on a pre-operative nucleosome liquid biopsy for lung cancer risk stratification.

What does the Nu.Q® Cancer Test aim to achieve?

The Nu.Q® Cancer Test aims to provide prognostic value for lung cancer patients.

Who are the authors of the presented poster?

The poster is authored by Pei-Hsing Chen and colleagues.

What event was the research presented at?

The research was presented at NACLC 2025.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare lung cancer Nu.Q® Cancer Test risk stratification NACLC 2025 biopsy
Last updated: Dec 8, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk